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Increasing evidence from both murine and human studies has indi-
cated that optimal antitumour responses require the participation
of both CD4+ Th and CD8+ cytotoxic T lymphocyte (CTL)
(Pardoll and Topalian, 1998). Originally it was thought that the
importance of Th cells was due to production of cytokines, partic-
ularly interleukin (IL)-2, which provided growth and differentia-
tion signals for precursor CTL to become effector CTL lysing the
autologous tumour (Simpson and Gordon, 1977; Keene and
Forman, 1982). More recent reports from several laboratories
including our own, however, have ascribed another function to
CD4+ T lymphocytes, namely the activation of antigen presenting
cells (APCs) so that they can effectively stimulate precursor CTL
to become effector CTL (Ridge et al, 1998; Schoenberger et al,
1998; Baxevanis et al, 2000). Recognition of the essential role of
CD4+ T lymphocytes for developing effective antitumour
responses has been accompanied by the identification of antigens
(Ags) on human tumours. Several MHC class I-restricted peptide
epitopes are derived from tumour Ags such as tyrosinase, gp100,
Melan-A, MART-1, MAGE-3 and NY-ESO-1 which have also
been demonstrated also to contain MHC class II-restricted
epitopes recognized by CD4+ T lymphocytes (Wang and
Rosenberg, 1999; Jaeger et al, 2000). 
The HER-2/neu proto-oncogene encodes a transmembrane glyco-
protein with extensive homology to epidermal growth factor receptor
whose cytoplasmic domain has tyrosine kinase activity (Hung and
Lau, 1999). Over-expression of HER-2/neu on many adenocarci-
nomas of breast and ovary is correlated with poor prognosis (Schultz
and Weber, 1999). In the past few years several peptide epitopes from
HER-2/neu have been clearly demonstrated to be recognized by
ovarian (Ioannides et al, 1991; Peoples et al, 1994; Yoshino et al,
1994; Fisk et al, 1995; Rongcun et al, 1999) and breast (Linehan et al,
1995; Peoples et al, 1995) cancer specific CTL. In addition to the
MHC class I-restricted epitopes, there is growing evidence that HER-
2/neu protein also contains helper epitopes. Thus, it has already been
shown that: (i) some patients with HER-2/neu positive cancers
produce IgG antibodies against the HER-2/neu protein (Disis et al,
1994) and (ii) CD4+ T cells from HER-2/neu-positive cancer patients
can proliferate and produce cytokines in response to synthetic
peptides or recombinant HER-2/neu protein (Disis et al, 1997; Fisk
et al, 1997; Tuttle et al, 1998). It is expected that using CTL and Th
peptide epitopes together in therapeutic vaccines may enhance their
effectiveness in clinical trials. 
The purpose of this study was to examine the potential use of
HER2(776–788) as a helper epitope and the identification of its
potential promiscuity (broad MHC restriction), so as to improve
the design of vaccination protocols of CTL-based immunotherapy
for tumours over-expressing HER-2/neu. We report here that
HER2(776–788) is a helper peptide naturally processed and
specifically recognized on tumour cells by CD4+ T cell clones in
vitro. HER2(776–788)-activated CD4+ T cells secrete large
amounts of IFN-γ , but not IL-4 or IL-10, which is suggestive of a
Th1 function of such cells stimulated by this peptide. One of 
the clones recognized HER2(776–788) in the context of either
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Summary HER2/neu-derived peptides inducing MHC class II-restricted CD4+ T helper lymphocyte (Th) responses, although critical for
tumour rejection, are not thoroughly characterized. Here, we report the generation and characterization of CD4+ T cell clones specifically
recognizing a HER-2/neu-derived peptide (776–788) [designated HER2(776–788)]. Such clones yielded specific proliferative and cytokine
[gamma-interferon(IFN)-γ ] responses when challenged with autologous dendritic cells (DCs) loaded with HER2(776–788). By performing
blocking studies with monoclonal antibodies (MAbs) and by using DCs from allogeneic donors sharing certain HLA-DR alleles, we found that
HER2(776–788) is a promiscuous peptide presented, at least, by DRB5*0101, DRB1*0701 and DRB1*0405 alleles. One TCRVbeta6.7+
clone recognized the HLA-DRB5*0101+ FM3 melanoma cell line transfected with a full length HER-2/neu cDNA. Moreover, this clone
recognized the HER-2/neu+ SKBR3 breast cancer cell line induced to express HLA-DR, thus demonstrating that HER2(776–788) represents
a naturally processed and presented epitope. Our data demonstrate that helper peptide HER2(776–788) represents a promiscuous epitope
binding to at least three HLA-DR alleles, thus offering a broad population coverage. The use of antigenic peptides presented by major
histocompatibility complex (MHC) class II in addition to those presented by class I may improve the therapeutic efficacy of active
immunization. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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high degree of promiscuity both in peptide binding to the class II
molecule, and in recognition of different MHC/peptide complexes
by the same TCR. These results may encourage the use of the
HER2(776–788) peptide along with HER-2/neu-derived CTL
epitopes in vaccination protocols for cancer patients of different
MHC types whose tumours over-express HER-2/neu. 
MATERIALS AND METHODS 
Cell lines 
The human breast adenocarcinoma cell line SKBR3 (American
Type Culture Collection, Manassas, VA) was cultured in McCoy’s
5A medium supplemented with 10% fetal bovine serum (FBS),
2mM L-glutamine and 50 µ g/ml gentamicin (all purchased 
from Life Technologies, Gaithersburg, MD). SKBR3 cells 
were induced to express HLA-DR molecules after a 4-day incuba-
tion with 150 U/ml human recombinant IFN-γ (Boehringer-
Mannheim, Mannheim, Germany) and human recombinant
tumour necrosis factor (TNF)-α 100U/ml (R&D System,
Abingdon, UK) in a CO2 incubator. The human melanoma cell line
FM3 (a kind gift of Dr J Zeuthen, Dept of Tumor Cell Biology,
Danish Cancer Society Research Center, Copenhagen) was grown
in RPMI 1640 (Life Technologies) with 10% FBS 2mM L-
glutamine and 50 µ g/ml gentamicin (complete medium). 
Purification of CD4+ T cells 
CD4+ T cells were isolated from PBMCs collected by standard
procedures from a healthy volunteer [HLA serotyping: HLA-A2, A3,
B44, B47, Cw6, DR15(2), DR4, DR51, DR53, DQ6(1), DQ8(3)]. 
Highly purified CD4+ T cells (>98% purity) were isolated using
Dynabeads (CD4 Positive Isolation Kit; Dynal, Oslo, Norway), as
recently described (Baxevanis et al, 1999). 
Generation of dendritic cells 
DCs autologous to the CD4+ T cells were generated from the
adherent fraction of freshly isolated PBMCs. Briefly, 4 × 106
PBMCs in 2 ml X-VIVO 15 (BioWhittaker, Walkersville, MD)
were plated in 6-well plates (Costar, Corning Inc., NY) and 
incubated for 2 h in a CO2 incubator. Non adherent cells were
gently washed out with Hanks’ Balanced Salt Solution (HBSS;
Life Technologies). The remaining plastic adherent cells were
cultured in 2 ml X-VIVO 15 medium supplemented with 1000
IU/ml IL-4 (R&D Systems, Europe) and 1000 IU/ml granulocyte
macrophage-colony stimulating factor (GM-CSF) (Immunex,
Seattle, WA). Fresh medium (2 ml) and cytokines were added on
days 2 and 4. For induction of maturation, TNF-α was added at 10
ng/ml on day 6. The nonadherent cell population was used on day
7 as a source of enriched mature dendritic cells or cryopreserved
for later use. The percentage of mature DCs recorded was > 50%,
as based on the CD3–, CD14–, CD16–, CD20–, CD40+, CD80+,
CD83+, CD86+, and HLA-DR+ phenotype analysed by flow
cytometry. Mature DCs were used as APCs pretreated with 70
µ g/ml mitomycin C (Kyowa, Tokyo, Japan) for 45 min at 37˚C.
After extensive wash with HBSS, DCs were pulsed with the
appropriate concentration of peptide for 4 h at 37˚C. 
HLA alleles presented in Table 1 were determined by standard
genotyping methods. Alleles HLA-DRB1*0401, *0404 and *0405
correspond to DR4, DRB1*1501 to DR15(2), DRB1*1101, 1104
to DR11(5), DRB*1601 to DR16(2), DRB1*0301 to DR17(3),
DRB1*1001 to DR10, DRB1*1401 to DR14(6), DRB1*0701 to
DR7, DRB5*0101 to DR51, DRB4*0101 to DR53, DRB3*0101
and *0201 to DR52. 
Peptide synthesis 
Synthesis of the HER-2(776–788) (GSPYVSRLLGICL) peptide
and of control peptides HER-2(884–899) (VPIKWMALE-
SILRRRF) (Fisk et al, 1997), gp100(44–59) (WNRQ-
LYPEWTEAQRLD) (Halder et al, 1997) and tyrosinase(448–462)
(DYSYLQDSDPDSFQD) (Topalian et al, 1996) was performed
with an Ecosyn P peptide synthesizer (Eppendorf-Biotronik,
Hamburg, Germany), using the Fmoc strategy and a 4-alcoxy-
benzyl alcohol resin. The peptides were assayed for purity 
by analytical HPLC, amino acid analysis and matrix-assisted 
laser desorption mass spectrometry. All peptides were determined
to be > 95% pure. Peptides were lyophilized, dissolved in
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Table 1
Donor (No.) HLA alleles Sla
1b DRB1*1501, 0404, DRB5*0101, DRB4*0101 2.9 
2 DRB1*1501, 1101, DRB5*0101, DRB3*0101 4.7 
3 DRB1*1601, DRB5*0101 3.9 
FM3-HERc DRB1*0201, 0401, DRB5*0101, DR53d 3.2 
5 DRB1*0301, DRB3*0201 1.1 
6 DRB1*0404, 0301, DRB3*0101, DRB4*0101 1 
7 DRB1*0404, 1104, DRB3*0201, DRB4*0101 1.2 
8 DRB1*1001, 1104, DRB3*0101 1.4 
9 DRB1*0401, 1401, DRB3*0101 1.3 
10 DRB1*0401, 1104, DRB3*0201, DRB4*0101 1.2 
11 DRB1*0405, 0404, DRB4*0101 3.3 
12 DRB1*0405, 1104, DRB3*0201, DRB4*0101 2.6 
13 DRB1*0701, 1104, DRB3*0201, DRB4*0101 2.8 
14 DRB1*0701, 1104, DRB3*0201, DRB4*0101 2.6 
SKBR3e DRB1*0701, 1302, DR52d, DR53d 3.1 
aDCs from the healthy donors listed above were used as APCs for HER2(776–788)
presentation to clone 2.1. bClone 2.1 was generated from PBMCs of donor No 1. cFM3
transfected with a HER-2/neu cDNA. dOnly serological typing was performed. eSKBR3
were treated with rIFN-γ +rTNF-α .phosphate-buffered saline (PBS), aliquoted at 2 mg/ml and stored
frozen at –20˚C until use (Reicher et al, 1996). 
Monoclonal antibodies and immunophenotyping 
MAbs to TCR α /β common and variable regions: Vβ 3.1,
Vβ 5(a), Vβ 6.7, Vβ 7.1, Vβ 8(a), Vβ 12, Vβ 13 and Vβ 17 conju-
gated with FITC were obtained from Endogen (Boston, MA).
Anti-CD83 conjugated with PE MAb was obtained from Caltag
Laboratories (Burlingame, CA). Anti-TCR Vβ 9 conjugated with
PE and anti-TCR Vβ 11, Vβ 5.1, Vβ 21, Vβ 13.6, Vβ 7, Vβ 22,
Vβ 16, Vβ 14, Vβ 20, Vβ 2 conjugated with FITC were purchased
from Serotec Ltd (Oxford, UK). Isotype matched anti-IgG
conjugated with FITC (IgG1, clone G18–145) was purchased
from Becton Dickinson (Mountain View, CA). All other MAbs
were obtained from PharMingen (San Diego, CA). Anti-CD4, 
-CD8, -CD16, -CD20, -CD40 and anti-CD80 were conjugated
with FITC. Anti-CD3, -CD14, -CD56, -CD86, -HLA-DR and
anti-TCR Vβ 23 MAbs were conjugated with PE. Samples were
analysed using FACScan (Becton Dickinson) and CellQuest
analysis software. For blocking experiments, purified azide-free
anti-HLA-DR (clone L243, IgG2a, κ ), anti-TNP, (clone
G155–178, IgG2a, κ ) (both from PharMingen), HLA-DP (clone
B7/21, Becton Dickinson) and anti-HLA-A,B,C (clone W6/32)
and anti-HLA-DQ (clone SPVL3) (both from Serotec) were
used. 
Generation of CD4+ T cell line and clones specific for
HER2(776–788) 
Highly purified CD4+ T cells were plated in 96-well U-bottom
plates (Costar) at 5 × 104 cells/well with 104 well autologous
mature DCs were pulsed with 25 µ g/ml HER-2 (776–788) peptide.
Cultures were set up in a final volume of 200 µ l X-VIVO 15
medium supplemented with 1% autologous heat-inactivated
plasma, 10 ng/ml IL-7 (R&D systems) and 100 pg/ml IL-12 (R&D
systems) in a CO2 incubator. Growing cultures were restimulated
at weekly intervals with DCs pulsed with 5 µ g/ml of the peptide.
After 3 days from the first restimulation, IL-2 (Chiron
Corporation, California) was added at 10 IU/ml. Peptide-specific
T cell clones were obtained from this bulk culture by limiting dilu-
tion. Cloning was accomplished in X-VIVO 15 medium supple-
mented with 0.5 µ g/ml PHA (Sigma), 1 IU/ml IL-2, 10 ng/ml
IL-7, 100 pg/ml IL-12 and mitomycin C treated allogeneic PBMCs
as feeders (2 × 104/well). 
Transfection of the FM3 cell line 
FM3 cells were co-transfected with a pSV2-c-erbB2 construct
(kindly provided by Dr Mien-Chie Hung, MD Anderson Cancer
Ctr, Houston, Texas) and a pSV2neo plasmid using DNA-
calcium phosphate co-precipitates as described (Graham and
van der Eb, 1973). Selection with G-418 (500 µ g/ml) was
started 48 h later. For cloning the cells were distributed into 96-
well flat bottom tissue culture plates (Costar) and stable trans-
fectants were selected. HER-2/neu-transfected FM3 lines were
subcloned until all cells were found to express HER-2/neu
(thereafter referred to as FM3/HER) as detected by FACS using
FITC-conjugated anti-HER-2/neu MAb (clone Neu 24.7) recog-
nizing the extracellular domain of HER-2/neu (Becton
Dickinson). 
Proliferation assay 
Responder CD4+ T cells (2× 104 cells/well) were co-cultured with
peptide (5 µ g/ml) pulsed or unpulsed autologous DCs (2× 103
cells/well) as APCs in 96-well U-bottom plates in a final volume
of 200 µ l X-VIVO 15 medium supplemented with 10 ng/ml IL-7
and 100 pg/ml IL-12. FM3 or FM3/HER cells and SKBR3 cells
(non-treated or treated with IFN-γ plus TNF-α ) were also used as
APCs at 2 × 103 cells/well. MAbs, wherever indicated, were added
at 10 µ g/ml final concentration throughout the culture period. On
day 4, 1 µ Ci/well tritiated thymidine ([3H]TdR, 48.0 Ci/mmol,
1mCi/ml, Amersham Pharmacia Biotech, Buckinghamshire, UK)
was added for the last 16 h. Cells were then harvested and [3H]TdR
incorporation was measured in a liquid scintillation counter (LKB
Wallac, Turku, Finland). All cultures were performed in triplicates
and results are expressed as counts per minute (cpm). Stimulation
index (SI) is calculated with cpm obtained in the presence of
antigen (i.e peptide-pulsed DCs, FM3/HER or treated SKBR3
cells) divided by cpm obtained in the absence of antigen (i.e.
unpulsed DCs, wild-type FM3 or untreated SKBR3 cells). 
ELISPOT assay 
96-well flat-bottomed Immobilon-P PVDF plates (Multi-Screen-
IP, Millipore, Bedford, MA) were coated overnight at 4˚C with 
2 µ g/ml anti-IFN-γ MAb (NIB42, PharMingen). Responder T 
cells were cultured in the 96-well nitrocellulose pre-coated 
plates at 2× 104 cells/well with autologous peptide (5 µ g/ml) 
pulsed or unpulsed DCs at 2× 103 cells/well in 200 µ l X-VIVO 15
medium supplemented with 1 IU/ml IL-2, 10ng/ml IL-7 and 100
pg/ml IL-12 for 24 h at 37˚C. After incubation, the plates were
washed extensively (with a solution of 0.05% Tween 20/PBS) 
and supplemented with the biotinylated anti-IFN-γ MAb (4S.B3,
PharMingen). Plates were incubated for 2 h at room temperature,
washed and developed with alkaline phosphatase-conjugated
streptavidin (Bio-Rad Laboratories, Hercules, CA) for another 1 h.
After washing, BCIP/NTB substrate (Bio-Rad) was used to
develop dark-violet spots. Spots were counted under a stereomi-
croscope (Zeiss, Germany). % inhibition of IFN-γ spots by the
HLA-DR MAb was calculated as follows: 
SI was calculated with the number of spots with peptide-pulsed
DCs divided by the number of spots with non-pulsed DCs. 
Quantitation of cytokines in culture supernatants 
IFN-γ , IL-4 and IL-10 secretion by HER2(776–788) specific CD4+
T cell clone 2.1 was estimated with commercially available ELISA
Kits (Diaclone Research, Besançon, France) according to the
manufacturer’s instructions. 
RESULTS 
Generation of a CD4+ T cell line specifically
recognizing HER2(776–788) 
A CD4+ T cell line from a healthy volunteer was established by
stimulation with HER2(776–788)-pulsed DC and was shown to be
specific for HER2(776–788) in proliferation assays. A strong
A promiscuous HLA-DR restricted epitope from HER-2/neu 1529
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no. of spots w/o MAb – no. of spots with MAb 
  100
no. of spots w/o MAbresponse was detected in the presence of autologous DCs 
pulsed with this peptide which was to a great extent blocked with
an anti-HLA-DR (MHC class II) MAb, but not with an isotype
matched control MAb or an anti-HLA-A,B,C (MHC class I) MAb
(Figure 1). MAb recognizing monomorphic determinants on MHC
class II molecules DP and DQ remained also without any effect
(Figure 1). The specificity of this CD4+ T cell line was further
tested against autologous DCs pulsed with irrelevant peptides
from HER-2/neu [HER2(884–899)], gp100 [gp(44–59)] or tyrosi-
nase [tyro(448–462)] all of which have been reported to be recog-
nized by CD4+ T cells in the context of HLA-DR molecules
(Topalian et al, 1996; Halder et al, 1997; Kobayashi et al, 2000).
As shown in Figure 2, none of these could significantly stimulate
proliferative response in the HER2(776–788) specific CD4+ T cell
line. The same line was unable to recognize the HLA-DR+, HER-
2/neu negative(–) FM3 melanoma cell line. However, it prolifer-
ated strongly upon stimulation with HER-2/neu-transfected FM3
cells (FM3/HER) and this response was also substantially blocked
in the presence of the anti-HLA-DR MAb (Figure 2). These data
suggested that the CD4+ T line specifically recognizes the HER-
2/neu peptide. Moreover, the significant recognition of FM3/HER
cells suggests that HER2(776–788) represents a naturally
processed and presented epitope. 
Generation and characterization of HER2(776–788)-
specific CD4+ T cell clones 
To better characterize the HER-2/neu peptide-specific response,
CD4+ T cell clones were generated. The CD4+ T line was cloned
by limiting dilution using allogeneic PBMCs as feeders. Of the
clones generated, eight proliferated in response to HER2(776–788)-
pulsed autologous DCs with a SI greater than 1.5 (range: 1.5–4.9)
(Figure 3). Moreover, all clones could recognize the FM3/HER, but
not the wild-type FM3 cells (SI range:1.7–4.9) (Figure 3).
HER2(776–788) peptide recognition was confirmed by using
ELISPOT assays. The same clones which significantly proliferated
in response to autologous DCs pulsed with HER2(776–788)
produced significant numbers of IFN-γ spots when similarly stim-
ulated (Figure 4). The SI observed in these experiments ranged
between 1.8 and 7.7 IFN-γ spots were considered significant when
the difference between the mean number from each peptide-stimu-
lated culture (every clone was tested in duplicates) was higher than
the mean number from all unstimulated cultures (mean value ± SD
from eight cultures:33 ± 7) plus 2SD (i.e. > 47), which was the
case in all clones tested. Similar to their parental CD4+ T-cell line,
all clones recognized HER2(776–788) in the context of HLA-DR
since their production of IFN-γ spots was greatly inhibited when
an anti-HLA-DR MAb was added at culture initiation (range of
inhibition:46–60%). 
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Figure 1 HER2(776–788) sensitized CD4+ T cells recognize in an HLA-DR
restricted fashion autologous DCs loaded with the same peptide. CD4+ T
cells from a healthy donor were sensitized with HER2(776–788) in long-term
cultures as described in ‘M+M’. After the 3rd restimulation (day 30) recovered
CD4+ T cells were tested as indicated in the proliferation assay. MAbs
specific for HLA-DR (L243), HLA-DQ (SPVL3), HLA-DP (B7/21) or HLA-class
I (W6/32) were added at 10 µ g/ml at culture initiation. Control MAb was an
anti-IgG2a,κ isotype matched with L243. Bars represent mean values ± SD
from triplicate cultures. One representative experiment out of three
conducted is shown 
DCs+HER+control Ab
DCs+HER+W6/32
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Figure 2 CD4+ T cells sensitized in vitro with HER2(776–788) specifically
recognize this peptide either loaded on DCs or naturally processed and
presented by the HLA-DR+ melanoma cell line FM3 transfected to express
HER-2/neu (FM3/HER). The same CD4+ T cells were tested as in Figure 1.
FM3 melanoma cells were transfected to express HER-2/neu as described in
‘M+M’. Bars represent means ± SD from triplicate cultures. One
representative experiment out of four conducted is shown 
Figure 3 Recognition of HER2(776–788) by a panel of CD4+ T cell clones.
All clones were generated from the CD4+ T cell culture that showed
specificity for HER2(776–788) in Figures 1 and 2. Cloning was performed as
described in ‘M+M’. Each clone was tested twice to ensure reproducibility of
the results and bars represent means ± SD from the two independently
performed experiments
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DCs+HER FM3 FM3 / HERHER2(776–788) recognition by clone 2.1 
CD4+ T cell clone 2.1 was propagated in vitro and functionally
characterized further. This clone was highly sensitive, recognizing
autologous HER2(776–788)-pulsed DCs with a half-maximal
proliferation at 0.8 µ g/ml of the peptide (Figure 5, filled symbol).
Anti-HLA-DR MAb significantly blocked the proliferation at all
peptide doses tested, thus proving that there was no mitogenic
effect mediated by the peptide at doses higher than 0.5 µ g/ml
(Figure 5, open symbols). The same clone also recognized the
peptide naturally processed and presented by both the FM3/HER
melanoma cells and the HER-2/neu+ SKBR3 breast cancer cells
induced to express HLA-DR upon preincubation with IFN-γ and
TNF-α . This was shown by means of proliferation (Figure 6A) and
IFN-γ secretion (Figure 6B). No IL-4 or IL-10 was produced by
clone 2.1 in response to FM3/HER and SKBR3 treated cells (data
not shown). 
Phenotypic analysis of clone 2.1 demonstrated that this was
CD4+TCRVB6.7+ (Figure 7). This clone did not express CD8,
CD56 or CD16. In addition, when tested with a series of TCRBV
MAbs other than anti-TCRVβ 6.7 (i.e. Vβ 3.1, Vβ 5(α ), Vβ 7.1,
Vβ 8(α ), Vβ 12, Vβ 13, Vβ 17, Vβ 11, Vβ 5.1, Vβ 21, Vβ 13.6, Vβ 7,
Vβ 22, Vβ 16, Vβ 14, Vβ 20, Vβ 2 and Vβ 23) it was also found nega-
tive (data not shown). 
The data so far suggested that HER2(776–788) is presented in
the context of HLA-DR and in particular of the HLA-DRB5*0101
allele which was shared between the FM3 melanoma cell line and
the donor of the T cell line (donor 1; Table 1). However, this
particular DR-allele was not identified in the SKBR3 cells which
express DRB1*0701, 1302, DR52 and DR53 after IFN-γ plus
TNF-α -treatment but nonetheless stimulate the clone (Table 1).
Therefore, to identify the HLA-DR alleles able to present the
peptide, we tested additional DCs from different donors for their
capacity to present this particular peptide to clone 2.1. We found
that these were capable of presenting the peptide only when
expressing one of the alleles: DR5*0101 (donors 1–3),
DRB1*0405 (donors 11,12) or DRB1*0701 (donors 13, 14) (SI
range: 2.6–4.7) (Table 1). From the same table it can be easily seen
that HER2(776–788) was not recognized by clone 2.1 when
presented by DRB1*0301 (donors 5,6), DRB1*0401 (donors
A promiscuous HLA-DR restricted epitope from HER-2/neu 1531
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Figure 5 Titration experiments. DCs pulsed with HER2(776–788) at the
indicated concentrations were used to stimulate clone 2.1 in the absence
(filled squares) or presence of anti-HLA-DR MAb (open circles). One
representative experiment out of three performed is shown. Data are shown
as means from triplicate cultures. The SD was negligible (<5% of the
means) and thus omitted 
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Figure 4 ELISPOT assays showing recognition of DCs pulsed with
HER2(776–788) by autologous CD4+ T cell clones. All clones were tested in
24 h cultures for recognition of autologous DCs either unpulsed or pulsed
with HER2(776–788). MAb specific for HLA-DR (L243) was tested for its
capacity to inhibit the IFN-γ production. Each clone was tested twice and
bars represent means ± SD from the two independently performed
experiments 
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Figure 6 SKBR3 cells induced to express HLA-DR and HLA-DR+
FM3/HER cells naturally process and present HER2(776–788) to clone 2.1
SKBR3 cells were preincubated with a combination of rIFN-γ plus rTNF-α
(SKBR3 treated) as described in ‘M+M’. Specific recognition of
HER2(776–788) by clone 2.1 was shown either as proliferation (A) or as 
IFN-γ secretion (B). Mean values ± SD from three independently performed
experiments are shown9,10), DRB1*0404 (donors 6,7), DRB1*1001 (donor 8),
DRB1*1104 (donor 7, 8, 10), DRB1*1401 (donor 9), DRB3*0101
(donors 6, 8, 9), DRB3*0201 (donors 5,7,10) and DRB4*0101
(donors 6,7,10). 
DISCUSSION 
The data presented herein characterize CD4+ T cell responses to
HER2(776–788), show direct recognition of this epitope on HER-
2/neu+ tumours and provide a rational basis for its use in T-cell
based cancer immunotherapy together with MHC class I
HER2/neu epitopes. In particular, we showed at the clonal level
that HER2(776–788) is capable of specifically activating CD4+ T
lymphocytes to strongly proliferate and produce high levels of
IFN-γ . By using the FM3 melanoma cell line transfected with
HER-2/neu (FM3/HER), as well as the HER2/neu+ SKBR3 breast
cancer cell line induced to express HLA class II molecules, we
demonstrated that HER2(776–788) represents a naturally
processed and presented epitope. Last, we have shown that the
same peptide was recognized by a CD4+ T lymphocyte clone in
the context of three different HLA-DR alleles, indicating a high
degree of histocompatibility and TCR promiscuity. 
Our studies show that HER2(776–788) can be recognized by a
monoclonal CD4+ T lymphocyte line, clone 2.1, in the context of
at least three different HLA-DR alleles, namely DRB5*0101,
DRB1*0701 and DRB1*0405. Southwood et al (1998) suggested
a motif for promiscuous binding peptides, characterized by a large
aromatic or hydrophobic residue in position 1 (p1) and a small,
noncharged residue in position 6 (p6). HER2(776–788) fulfils
these criteria, as it bears Tyr and Val, either of which could be a
potential candidate for p1 and also Leu and Gly that could fit at p6.
DRB5*0101 and DRB1*0701 alleles are characterized by largely
overlapping peptide-binding repertoires and they belong to a
single DR supertype according to Southwood et al (1998). The
same peptides also exhibit significant frequencies of cross-
reactivity with a group of three other alleles including DRB1*0405
(Southwood et al, 1998). Taken together all these findings satisfac-
torily explain the binding of HER2(776–788) to the three different
DR alleles. Considering also recent data published by Anderson et al
(2000) who could induce a response to HER2(776–788) in two
donors sharing HLA-DR11 molecule we may ascribe a high degree
of promiscuity to this particular peptide. A similar finding has been
recently described by Kobayashi et al (2000) which demonstrated
recognition of HER2/neu-derived peptide (883–899) presented by
HLA-DR1, HLA-DR4, HLA-DR52 and HLA-DR53 molecules. 
Despite the high degree of specificity of ligand recognition by
TCRs, several reports have described antigen specific T cells that
can recognize and respond to diverse MHC molecules (Karr et al,
1991; Hemmer et al, 2000). Doherty et al (1998) have reported the
recognition of a herpes simplex virus peptide by a T lymphocyte
clone presented in the context of several DR alleles. Hypervariable
regions HVR3 of DRβ polypeptides encompassing residues 67–71
and in particular residue 71 have been demonstrated to exert a
central role in peptide binding and allorecognition (Coppin et al,
1993; Martinez-Soria et al, 1994; McKinney et al, 1994). In addi-
tion, position 86 has also been described to affect TCR allorecogni-
tion (Busch et al, 1991; Demotz et al, 1993; Zeliswewski et al,
1993). HLA-DRB5*0101, DRB1*0701 and DRB1*0405 alleles
display largely overlapping aminoacid sequences at positions 67–71
and 86 (Table 2) and this may account for the recognition by the
same TCR of the peptide complexed to distinct MHC molecules. 
The procedure described here proved to be efficient for 
optimal activation of anti-HER2 (776–788) CD4+ T cell precur-
sors present in the PBMC from our healthy donor, and for the
resulting isolation of the peptide-specific CD4+ T lymphocyte
clones. Bulk CD4+ T lymphocytes proliferated specifically in an
HLA-DR restricted fashion with high stimulation indices in
response to autologous DCs pulsed with HER2(776–788). T cell
clones established from these cells strongly proliferated and
produced high levels of IFN-γ in response to autologous DCs
pulsed with the HER2(776–788) peptide, suggesting that under the
conditions used HER2(776–788) peptide functions as a Th
peptide. Clone 2.1, which could be further propagated, was used to
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Figure 7 Staining of HER2(776–788) specific clone 2.1. Cells were incubated with FITC conjugated anti-CD4 (left panel) or anti-TCRVβ 6.7 (right panel).
Negative control cells were stained with an FITC-conjugated isotype matched MAb 
Table 2
HLA-allelea 67 68 69 70 71 86 
DRB5*0101 F L E D R G 
DRB1*0701 I L E D R G 
DRB1*0405 L L E Q R G 
aFor more details see ref. (Demotz et al, 1993; McKinney et al, 1994;
Doherty et al, 1998). 
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derived peptides. For this, the HLA-DR51+ FM3 melanoma cell
line was transfected with a full-length HER-2/neu cDNA
(FM3/HER) and specific recognition by this particular clone
measured as proliferation and IFN-γ (but not IL-4 or IL-10) secre-
tion was shown. That HER2(776–788) is a naturally processed and
presented peptide was confirmed by using the SKBR3 breast
cancer cell line, which overexpresses HER-2/neu without enforced
expression by transfection. This cell line expresses, in our hands,
the HLA-DR7, -13, -52 and -53 alleles upon treatment with a
combination of IFN-γ plus TNF-α (Table 1) and exhibits enhanced
expression of costimulatory molecules CD80 and CD86 (unpub-
lished data). Clone 2.1 recognized the IFN-γ plus TNF-α -treated
SKBR3 cells in a fashion similar to that with the FM3/HER cells
(Figure 6), thus confirming that HER2(776–788) is naturally
processed and presented on the surface of carcinomas. 
This again suggests that HER-2/neu possesses lysosomal
targeting sequences that enables it to present its peptides in the
context of class II molecules. Indeed, some patients with breast
cancer produce anti-HER-2/neu IgG antibodies (Cheever et al,
1995), suggesting that HER-2/neu is presented to CD4+ T
lymphocytes in vivo. Since breast tumour cells usually do not
express class II molecules, this can be achieved by the uptake of
tumour cell apoptotic bodies by macrophages or dendritic cells.
The HER-2/neu molecule therefore represents a source of natu-
rally processed and presented peptides capable of stimulating both
CD8+ and CD4+ T-lymphocyte responses in vivo. Based on recent
data from us (Baxevanis et al, 2000) and others (Ridge et al, 1998;
Schoenberger et al, 1998) on CTL-Th collaboration models, it may
be hypothesized that HER-2/neu specific CD4+ T lymphocytes
can function in vivo as ‘activators’ of APCs so that they can stim-
ulate directly HER-2/neu recognizing CD8+ T lymphocytes to
become effector CTLs. Work is now in progress in our laboratory
to address this hypothesis. 
Taken together the data presented in this report strongly suggest
that peptide HER2(776–788) represents a candidate helper epitope
to be included in vaccine preparation consisting of HER-2/neu
peptides presented by MHC class I and class II molecules. With
such formulations vaccine-induced HER-2/neu-specific CD4+ 
T-lymphocyte responses may synergize with vaccine-induced
CTL, resulting in improved antitumour responses. The finding that
this peptide is presented in the context of three DR alleles is
advantageous since: (i) it may induce higher frequency of clones
recognizing it and thus a more massive anti-tumour response; and
(ii) it offers a broad population coverage. The identification of
tumour protein-derived Th epitopes will be useful for the design of
clinical protocols aiming at the improvement of clinical results in
cancer immunotherapy. 
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